Vivos Therapeutics Inc. (NASDAQ: VVOS) reported revenue of $5.1 million for the first quarter ended March 31, 2026, representing a 70% increase from $3.0 million in the same period last year, according to the company's financial results released May 20, 2026.

The revenue growth was primarily driven by the company's June 2025 acquisition of The Sleep Center of Nevada, which contributed approximately $2.0 million in sleep testing services and $0.9 million from treatment protocols at two locations.

Gross profit increased 103% to $3.1 million compared to $1.5 million in the prior year quarter, with gross margin improving to 60% from 50%. The company reported a net loss of $7.8 million, or $0.52 per share, compared to a net loss of $3.9 million, or $0.45 per share, in the first quarter of 2025.

Operating expenses rose 78% to $9.7 million from $5.4 million, which the company attributed to personnel and costs related to business expansion. Approximately $0.9 million of the increase consisted of professional fees that are not expected to recur throughout the remainder of the year.

Oral appliance sales increased 42% to 5,304 units versus 3,735 units in the first quarter of 2025. However, product revenue from sales to legacy dentist customers decreased to $1.4 million from $1.8 million due to higher volumes of lower-priced tooth positioners.

Cash and cash equivalents totaled $2.1 million at March 31, 2026, while stockholders' equity showed a deficit of $1.1 million. The company had no new enrollments of dentists during the quarter as it continues its business model transition following the acquisition.

Vivos develops medical devices for treating breathing-related sleep disorders, including obstructive sleep apnea. The company is based in Littleton, Colorado.